The humanized anti-VEGF monoclonal antibody Bevacizumab was regarded as an effective treatment option for metastatic or recurrent cervical cancer, owing to the role of vascular endothelial growth factor (VEGF) in promoting angiogenesis [3]. This evidence concerns the gene VEGFA and cervical carcinoma.